3Jack C, Ivana S, Simon C, et al. Tamoxifen for prevention of breast cancer: extended long term follow-up of the IBIS-I breast cancer prevention trial[J].Lancet Oncol,2015; 16: 67-75.
4Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial[J].Lancet, 1998, 352:98-101.
5Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial[J].J Natl Cancer Inst, 2007, 99: 283-290.
6Nichols HB, DeRoo LA, Scharf DR, et al. Risk-benefit profiles of women using tamoxifen for chemoprevention[J].JNCI J Natl Cancer Inst, 2015: 1-8.
7Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline[J].J Clin Oncol, 2013, 49(3122): 4361-4383.
8蔡德山. 抗乳腺癌药领跑者风头不减[N]. 医药经济报, 2015-1-28(4).
9Herold CI, Blackwell KL. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer[J].Breast, 2008, 17(S1): S15-S24.
10Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer[J].J Clin Oncol, 2010, 28( 23) : 3784-3796.
